|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||510.05 - 522.15|
|52-week range||432.70 - 730.95|
|PE ratio (TTM)||27.47|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
REUTERS - India's largest drugmaker Sun Pharmaceutical Industries reported a 59 percent plunge in second-quarter profit on Tuesday, hurt by generics pricing pressure in the United States. Along with other ...
Sun Pharmaceutical Industries Ltd.’s profit more than halved as it lost exclusivity on a key U.S. product, increasing pressure on the company to resolve issues at a plant that has hampered new product ...
REUTERS - Indian shares extended gains on Thursday with the NSE index clocking its biggest percentage gain since May 25 as excitement builds up ahead of some key quarterly results including that from Tata ...
Mumbai, Sep 6 (IANS) Negative global cues, coupled with heavy selling pressure in index heavyweights like Sun Pharma and ITC and substantial outflow of foreign funds, pulled key Indian equity indices -- ...
India's largest drugmaker Sun Pharmaceutical Industries Ltd posted a surprise quarterly loss on Friday due to one-off legal costs and pressure over prices in its largest market, the United States, casting a shadow over its growth prospects. Sun is the latest maker of generic drugs to report poor sales as uncertainty grows in the global market for copycat drugs due to rising competition and pricing scrutiny in the United States. India's drugs industry, the world's fourth largest, has been hit particularly hard due also to challenges at home, where the government is tightening control over prices, and a nationwide tax reform has hit supplies.
Mumbai, Aug 11 (IANS) Sun Pharmaceutical Industries Ltd on Friday reported a huge net loss of Rs 1,291 crore for the first quarter (Q1) of fiscal 2017-18 on standalone basis, which is over eight times the net loss of Rs 152 crore incurred in the same period year ago. In a regulatory filing on the BSE, the leading drug maker said standalone revenue from operations for the quarter under review (Q1) was flat at Rs 1,803 crore as against Rs 1,800 crore in the like period year ago. Sequentially, revenue declined 11 per cent in Q1 from Rs 2,017 crore quarter ago when the net profit was Rs 95 crore.
Mumbai, June 13 (IANS) Drug major Sun Pharmaceutical Industries on Tuesday announced that one of its wholly owned subsidiaries has received final approval from the US Food and Drug Administration (USFDA) ...
By Krishna V Kurup REUTERS - India's benchmark BSE Sensex edged higher to a record close for a third consecutive session as consumer goods stocks gained, but broader advances were capped by falls in companies ...
India's largest drug group Sun Pharmaceutical Industries Ltd said on Friday its U.S. sales might fall this year because of pressure on drug prices, signalling tough market conditions in the United States for generic drugmakers. "The U.S. generics industry is facing rapidly changing market dynamics, (and) increased competitive intensity and customer consolidation is leading to pressure on pricing," Sun's Managing Director Dilip Shanghvi said on a call with analysts after the company reported lower than expected fourth-quarter earnings.
Mumbai, May 24 (IANS) Drug major Sun Pharmaceutical Industries Ltd on Wednesday said the US Food and Drug Administration (USFDA) has accepted its Biological License Application (BLA) for tildrakizumab. In a statement issued here Sun Pharmaceuticals said the USFDA filing acceptance follows the acceptance of the regulatory filing of tildrakizumab by the European Medicines Agency (EMA) in March 2017. "The acceptance of the regulatory filing by the US FDA marks a significant milestone as we seek to advance for tildrakizumab as a potential new treatment option for people who continue to struggle everyday with the chronic nature of psoriasis," Abhay Gandhi, CEO - North America Business, Sun Pharmaceuticals, was quoted as saying in the statement.
India's largest drugmaker Sun Pharmaceutical Industries said U.S. regulators plan to lift a ban on its Mohali plant in northern India, paving the way for a resumption of exports to the company's biggest market after four years. The move would come as a boost to Sun, whose U.S. growth has been hit over the past year as five of its plants face supply restrictions due to regulatory issues. Sun said on Tuesday the U.S. Food and Drug Administration (FDA) had informed it about the agency's plans to lift the ban on Mohali.
REUTERS - Indian shares retreated from near two-year highs to end lower on Thursday as investors booked profit in pharmaceutical and realty stocks such as Sun Pharmaceutical Industries and DLF Ltd. The ...
REUTERS - Indian shares ended at their lowest in two weeks on Wednesday, with Tata Motors pulling the indexes down after posting disappointing results. The benchmark BSE Sensex fell 0.65 percent to 28,155.56, ...
Sun Pharmaceutical Industries, India's largest drugmaker, reported its first fall in quarterly profits in a year on Tuesday, as pricing issues and supply constraints affected sales in the United States, its largest market. Sun's U.S. business faces increasing uncertainty as it struggles to fix quality control problems found by regulators at its key drug factories, and is the subject of a U.S. Department of Justice investigation into increases in drug prices. "The idea for us is to improve our supply and regain market share ... our plan is to create a very successful specialty business," billionaire founder and Managing Director Dilip Shanghvi told analysts on a conference call.
Sun Pharmaceutical Industries Ltd (SUN.NS), India's largest drugmaker, said on Wednesday the U.S. health regulator has informed the company of more concerns found at its Halol manufacturing plant after a recent inspection. The approval of several of Sun's key drugs in the United States, the drugmaker's biggest market, depends on the clearance on its Halol plant in the western Indian state of Gujarat. A warning letter issued by the U.S. Food and Drug Administration (FDA) last year over violations found at the plant has already been hurting the company's sales.